Surgical Oncology Principles — MCQs

Q: What is the definition of a sentinel lymph node?

The primary lymph node draining the tumor.. ### Explanation **Concept Overview** The **Sentinel Lymph Node (SLN)** is defined as the first lymph node (or group of nodes) in a regional lymphatic basin that receives direct lymphatic drainage from a primary tumor. The underlying physiological principle is that lymphatic metastasis occurs in an orderly, step-wise fashion. If the sentinel node is negative for malignancy, there is a high probability (usually >95%) that the remaining nodes in that basin are also free of disease. **Analysis of Options** * **Option A (Correct):** This aligns with the physiological definition. It is the "gatekeeper" node. If the tumor spreads via lymphatics, this node is the first site of metastasis. * **Option B (Incorrect):** A Modified Radical Mastectomy (MRM) involves a formal axillary lymph node dissection (Levels I and II). The nodes removed are based on anatomical boundaries, not necessarily the specific drainage pattern of the tumor. * **Option C (Incorrect):** Proximity does not always equal drainage. Due to the complexity of lymphatic channels, the sentinel node may sometimes be anatomically distant from the tumor while still being the first node to receive its drainage. **Clinical Pearls for NEET-PG** * **Identification:** SLN is identified using **Isosulfan blue/Methylene blue dye** (visualized) and/or **Technetium-99m labeled sulfur colloid** (detected via a gamma probe). * **Most Common Indications:** Breast cancer (T1/T2 lesions) and Malignant Melanoma. * **Skip Metastasis:** This refers to a phenomenon where the SLN is negative, but higher-level nodes are positive. While rare, it is a limitation of SLN biopsy. * **Contraindications in Breast Cancer:** Inflammatory breast cancer, multicentric tumors (relative), and clinically palpable axillary nodes (N1/N2).

Q: What is the definition of neoadjuvant chemotherapy?

Chemotherapy administered prior to surgery. **Explanation:** **Neoadjuvant chemotherapy** refers to the administration of systemic cytotoxic agents **prior to the primary definitive treatment** (usually surgery). The primary goal is to downstage the tumor, increase the likelihood of a complete (R0) resection, and treat micrometastatic disease early. * **Why Option B is Correct:** The prefix "neo-" (new/before) and "adjuvant" (assisting) signifies therapy given before the main intervention. By shrinking the primary tumor, it can convert an inoperable case into an operable one or allow for breast-conserving surgery instead of a mastectomy. * **Why Options A, C, and D are Incorrect:** * **Option A:** Chemotherapy is rarely given *during* the surgical procedure itself (except for specialized techniques like HIPEC). * **Option C:** This describes **Adjuvant Chemotherapy**, which is given *after* surgery to eliminate residual microscopic disease and reduce recurrence risk. * **Option D:** This describes **Concurrent Chemoradiotherapy (CCRT)**, often used as definitive treatment in cancers like Carcinoma Cervix or Esophagus. **NEET-PG High-Yield Pearls:** 1. **Pathological Complete Response (pCR):** The gold standard for measuring the effectiveness of neoadjuvant therapy; it implies no viable tumor cells remain in the surgical specimen. 2. **Common Indications:** Locally advanced breast cancer (LABC), esophageal cancer, and rectal cancer (often as neoadjuvant chemoradiation). 3. **Window of Opportunity:** It provides an *in vivo* assessment of how sensitive the tumor is to a specific chemotherapy regimen.

Q: In TNM classification, what does T3 stand for regarding tumor size?

Tumor size >4 cm. The **TNM classification** is the global standard for staging malignant tumors, where **T** describes the size and extent of the primary tumor. In many common solid organ cancers (such as Oral Cavity, Skin, and Salivary Glands), the "Rule of 2s" is often applied for T-staging. ### **Explanation of the Correct Answer** **Option B (>4 cm)** is correct because, in the standard AJCC staging for several major sites (like the oral cavity), the T-stage is defined by size thresholds: * **T1:** ≤2 cm * **T2:** >2 cm but ≤4 cm * **T3:** **>4 cm** (limited to the organ of origin) ### **Analysis of Incorrect Options** * **Option A (>2 cm):** This represents the lower limit for **T2** lesions. A tumor >2 cm but ≤4 cm is classified as T2. * **Option C ( 4 cm with invasion):** While the size is correct, the addition of "invasion of adjacent structures" (like cortical bone, deep tongue muscles, or maxillary sinus) typically upgrades the tumor to **T4a or T4b** (Advanced Local Disease), regardless of the size. ### **High-Yield Clinical Pearls for NEET-PG** 1. **T0 vs. Tis:** T0 means no evidence of a primary tumor, while **Tis** stands for Carcinoma *in situ* (pre-invasive). 2. **Clinical vs. Pathological:** **cTNM** is based on physical exam and imaging; **pTNM** is based on histopathological examination of the resected specimen. 3. **Depth of Invasion (DOI):** In the latest AJCC 8th Edition (Oral Cavity), T-staging now incorporates DOI. For example, a T3 tumor is also defined as any tumor with a **DOI >10 mm**, even if the surface diameter is small. 4. **Sentinel Node Biopsy:** This is the most accurate method for "N" staging in early-stage (T1/T2) tumors with clinically negative necks (cN0).

Q: A tumor is represented as T3N2M0. What stage does this indicate?

Stage 4. ### Explanation The TNM staging system (Tumor, Node, Metastasis) is the global standard for classifying the extent of cancer. In this case, the tumor is staged as **T3N2M0**, which corresponds to **Stage 4** (specifically Stage IV in many solid tumor classifications like Head and Neck or certain GI cancers). **1. Why Stage 4 is Correct:** In the TNM hierarchy, the involvement of regional lymph nodes is a significant prognostic indicator. While "Stage 4" is often associated with distant metastasis (M1), in several major staging systems (such as the AJCC 7th/8th editions for various squamous cell carcinomas), **N2 or N3 nodal involvement** automatically upgrades the disease to Stage IV, even in the absence of distant metastasis (M0). This reflects a high regional tumor burden and a prognosis similar to metastatic disease. **2. Why Other Options are Wrong:** * **Stage 1:** Typically represents small, localized tumors (T1) without any nodal involvement (N0) or metastasis (M0). * **Stage 2:** Usually involves larger localized tumors (T2) but still maintains an N0 status. * **Stage 3:** Generally involves T3 tumors with N0 or limited N1 nodal involvement. Once the nodal status reaches **N2**, the disease typically crosses the threshold into Stage 4. **3. NEET-PG High-Yield Pearls:** * **M1 = Always Stage 4:** Regardless of T or N status, any distant metastasis (M1) is automatically Stage IV. * **Nodal Status:** For many cancers, N0 = Stage I/II, N1 = Stage III, and N2/N3 = Stage IV. * **Exceptions:** Note that staging varies by organ (e.g., in Papillary Thyroid Cancer, age <55 years means any TNM without M1 is Stage I). * **Clinical vs. Pathological:** 'cTNM' is based on imaging/exam; 'pTNM' is based on surgical histopathology.

Q: A 60-year-old male is diagnosed with carcinoma of the right lung. CECT of the chest shows a 5x5 cm tumor in the upper lobe and another 2x2 cm tumor nodule in the middle lobe. Which of the following is the treatment of choice?

Surgery. ### Explanation **Correct Option: A. Surgery** The patient presents with two separate tumor nodules in different lobes of the same lung (Right Upper Lobe and Right Middle Lobe). According to the **TNM 8th Edition Staging System** for Lung Cancer: * Tumor nodules in the **same lobe** are classified as **T3**. * Tumor nodules in **different lobes of the same lung** are classified as **T4**. Despite being T4, if there is no evidence of mediastinal lymphadenopathy (N0/N1) or distant metastasis (M0), the disease is classified as **Stage IIIA**. In modern surgical oncology, Stage IIIA (T4N0-1) lung cancer is considered **resectable**. The treatment of choice is a surgical resection (e.g., pneumonectomy or bilobectomy) provided the patient has adequate pulmonary reserve. **Why Incorrect Options are Wrong:** * **B. Radiotherapy:** Primarily used for Stage IIIB/IV or in patients who are medically unfit for surgery. It is not the first-line treatment for resectable T4 disease. * **C. Chemotherapy:** Often used as neoadjuvant or adjuvant therapy in Stage III disease, but it is not the definitive "treatment of choice" when surgical cure is possible. * **D. Supportive treatment:** Reserved for end-stage (Stage IV) palliative care where curative intent is no longer feasible. **High-Yield Clinical Pearls for NEET-PG:** 1. **T-Staging Summary:** * Same Lobe = T3 * Same Lung (different lobe) = T4 * Opposite Lung = M1a 2. **Resectability vs. Operability:** Resectability depends on the tumor stage (TNM), while operability depends on the patient's fitness (FEV1, cardiac status). 3. **Gold Standard:** For early-stage Non-Small Cell Lung Cancer (NSCLC), anatomical resection (Lobectomy) with mediastinal lymph node dissection remains the gold standard.

Q: Elevated alpha-fetoprotein (AFP) levels are seen in all of the following conditions except:

Seminoma. **Explanation:** Alpha-fetoprotein (AFP) is a glycoprotein normally produced by the fetal yolk sac and liver. In adult medicine, it serves as a crucial tumor marker for specific germ cell tumors (GCTs) and hepatocellular carcinomas. **Why Seminoma is the Correct Answer:** Pure **Seminomas** (and their ovarian counterpart, Dysgerminomas) **never** produce AFP. If a patient diagnosed with a seminoma shows elevated AFP levels, it indicates the presence of a "mixed germ cell tumor" containing yolk sac elements, and the clinical management must change accordingly. Seminomas are typically associated with elevated **hCG** (in 10-15% of cases) and **LDH**, but never AFP. **Analysis of Other Options:** * **Hepatoblastoma:** This is the most common primary liver tumor in children. It is characterized by extremely high levels of AFP, which is used for both diagnosis and monitoring treatment response. * **Teratoma:** While pure mature teratomas may not secrete markers, teratomas are frequently part of mixed germ cell tumors. In the context of NEET-PG questions, AFP is considered a marker for non-seminomatous germ cell tumors (NSGCTs), which includes yolk sac tumors, embryonal carcinomas, and certain teratomas. **High-Yield Clinical Pearls for NEET-PG:** 1. **Yolk Sac Tumor (Endodermal Sinus Tumor):** This is the most specific tumor associated with high AFP levels (100% of cases). Look for **Schiller-Duval bodies** on histology. 2. **Hepatocellular Carcinoma (HCC):** AFP is the primary screening marker; levels >400 ng/mL in a high-risk patient are highly suggestive. 3. **Rule of Thumb:** * **AFP ↑:** Yolk sac tumor, HCC, Hepatoblastoma. * **hCG ↑:** Choriocarcinoma (100%), Seminoma (15%). * **LDH ↑:** Seminoma (marker of tumor burden/bulk).

Q: Which of the following statements is NOT true regarding familial polyposis coli?

It is inherited in an autosomal recessive pattern.. ### Explanation **1. Why Option A is the Correct Answer (The False Statement):** Familial Adenomatous Polyposis (FAP) is inherited in an **Autosomal Dominant** pattern, not recessive. It is caused by a germline mutation in the **APC (Adenomatous Polyposis Coli) gene** located on chromosome **5q21**. According to Knudson’s "two-hit hypothesis," an individual inherits one defective allele, and a somatic mutation in the second allele leads to the development of hundreds to thousands of adenomatous polyps. **2. Analysis of Other Options:** * **Option B (Associated with fibromas and osteomas):** This describes **Gardner Syndrome**, a variant of FAP. It includes intestinal polyposis plus extra-colonic manifestations like osteomas (commonly of the mandible), dental abnormalities, and soft tissue tumors (desmoid tumors, fibromas). * **Option C (Associated with brain tumors):** This describes **Turcot Syndrome**, another variant where FAP is associated with CNS malignancies (classically medulloblastoma). * **Option D (100% incidence of colon carcinoma):** This is a hallmark of FAP. If left untreated by prophylactic total proctocolectomy, the progression from adenoma to adenocarcinoma is inevitable, usually by the age of 40. **3. High-Yield Clinical Pearls for NEET-PG:** * **Diagnosis:** Requires >100 polyps on colonoscopy. * **Screening:** Starts at age **10–12 years** with annual flexible sigmoidoscopy. * **Extra-colonic Malignancy:** The second most common cause of death in FAP patients (after colorectal cancer) is **Periampullary Carcinoma** (Duodenal cancer). * **CHRPE:** Congenital Hypertrophy of Retinal Pigment Epithelium is a specific clinical sign seen on fundoscopy in FAP patients.

Q: What is the most common symptom of bronchial adenoma?

Recurrent hemoptysis. **Explanation:** **Bronchial adenomas** (a term historically used to describe a group of low-grade malignant tumors, primarily **Bronchial Carcinoids**) are highly vascular, slow-growing epithelial tumors that typically arise from the central airways (main or lobar bronchi). 1. **Why Recurrent Hemoptysis is Correct:** The hallmark of bronchial adenomas is their **extreme vascularity** and their tendency to grow as endobronchial polypoid masses. Because they arise from the bronchial mucosa and are richly supplied by blood vessels, the overlying mucosa is fragile. Even minor trauma from coughing or tumor erosion leads to **recurrent, often brisk, hemoptysis**. This is the most common presenting symptom, occurring in approximately 50–80% of cases. 2. **Why Other Options are Incorrect:** * **Cough:** While cough is a common symptom due to endobronchial irritation or obstruction, it is non-specific and often secondary to the bleeding or localized collapse. * **Chest Pain:** This is usually a late feature, occurring only if the tumor involves the pleura or causes significant obstructive pleurisy/pneumonia. * **Weight Loss:** Unlike Bronchogenic Carcinoma (Small cell or Squamous cell), bronchial adenomas are slow-growing and rarely cause systemic paraneoplastic "wasting" or cachexia early in the disease. **Clinical Pearls for NEET-PG:** * **Most Common Type:** Carcinoid tumor (80–90% of "adenomas"). * **Classic Presentation:** A young patient (often non-smoker) presenting with recurrent hemoptysis and localized wheeze or "unresolved pneumonia" (due to ball-valve obstruction). * **Diagnosis:** Bronchoscopy is the gold standard as most are central. However, biopsy carries a **high risk of bleeding** due to vascularity. * **Carcinoid Syndrome:** Rare in bronchial carcinoids (unlike GI carcinoids) unless there are extensive liver metastases.

Q: Which lymph node is involved in M1 stage of gallbladder cancer?

Inter-aortocaval node. ### Explanation In gallbladder cancer (GBC), the lymphatic drainage follows a predictable, sequential pattern. Understanding the distinction between **regional** and **distant** lymph nodes is crucial for accurate TNM staging. **1. Why Option A is Correct:** According to the **AJCC 8th Edition** staging for gallbladder cancer, the **inter-aortocaval nodes** (located behind the head of the pancreas and around the great vessels) are considered **distant lymph node metastases (M1)**. Involvement of these nodes signifies systemic spread, rendering the disease unresectable for curative intent. **2. Why the Other Options are Incorrect:** The lymphatic spread of GBC occurs in three levels, all of which are considered **regional (N-stage)**, not distant (M-stage): * **Level I (N1):** Includes the cystic duct node (Lund’s/Calot’s node) and pericholedochal nodes. * **Level II (N2):** Includes the **pancreaticoduodenal (Option D)**, peripancreatic (head only), and portal vein nodes. * **Level III (N2):** Includes the **coeliac (Option C)** and **superior mesenteric (Option B)** nodes. * *Note:* While Options B, C, and D represent advanced nodal involvement (N2), they are still classified under the "N" category. Only nodes beyond these, like the inter-aortocaval or para-aortic nodes, transition the stage to **M1**. **High-Yield Clinical Pearls for NEET-PG:** * **Most common site of distant metastasis:** Liver. * **Sentinel node of the gallbladder:** Lund’s node (Node of Calot). * **N-staging update:** AJCC 8th edition now classifies N stage based on the *number* of positive nodes (N1: 1–2 nodes; N2: ≥3 nodes), but the anatomical boundary for M1 remains the inter-aortocaval/para-aortic station. * **Investigation of choice:** Contrast-Enhanced CT (CECT) is the gold standard for staging and assessing resectability.

Q: What are the risk factors for anal carcinoma?

All of the above. **Explanation:** Anal carcinoma (specifically Squamous Cell Carcinoma) shares a similar pathophysiology with cervical cancer, primarily driven by persistent infection with high-risk strains of **Human Papillomavirus (HPV)**, most commonly types 16 and 18. * **HPV Infection (Option A):** This is the most significant risk factor, present in over 80-90% of cases. The virus integrates into the host genome, leading to the overexpression of E6 and E7 oncoproteins, which inactivate tumor suppressor genes p53 and Rb. * **Smoking (Option B):** Cigarette smoking is an independent risk factor for anal cancer. Carcinogens in tobacco smoke can reach the anal mucosa through systemic circulation or local deposition, promoting malignant transformation. * **Cervical Carcinoma (Option C):** Patients with a history of cervical, vaginal, or vulvar dysplasia/carcinoma are at a significantly higher risk. This is due to the "field effect" of HPV infection across the anogenital tract and shared lymphatic drainage patterns. **Clinical Pearls for NEET-PG:** 1. **HIV Status:** HIV-positive individuals (especially MSM - men who have sex with men) have the highest incidence of anal cancer due to immunosuppression and increased HPV prevalence. 2. **Anal Intraepithelial Neoplasia (AIN):** This is the precursor lesion (similar to CIN in the cervix). 3. **Anatomy:** Tumors above the dentate line are typically columnar/transition zone, while those below are squamous. 4. **Treatment:** Unlike most GI cancers, the primary treatment for anal canal SCC is **Nigro Protocol** (Chemoradiotherapy with 5-FU and Mitomycin C), not surgery. Surgery (Abdominoperineal Resection) is reserved for salvage.

Surgical Oncology Principles Indian Medical PG Practice Questions and MCQs

Question 1: What is the definition of a sentinel lymph node?

A. The primary lymph node draining the tumor. (Correct Answer)
B. The first lymph node excised during a modified radical mastectomy.
C. The lymph node located nearest to the tumor.
D. None of the above.

Explanation: ### Explanation **Concept Overview** The **Sentinel Lymph Node (SLN)** is defined as the first lymph node (or group of nodes) in a regional lymphatic basin that receives direct lymphatic drainage from a primary tumor. The underlying physiological principle is that lymphatic metastasis occurs in an orderly, step-wise fashion. If the sentinel node is negative for malignancy, there is a high probability (usually >95%) that the remaining nodes in that basin are also free of disease. **Analysis of Options** * **Option A (Correct):** This aligns with the physiological definition. It is the "gatekeeper" node. If the tumor spreads via lymphatics, this node is the first site of metastasis. * **Option B (Incorrect):** A Modified Radical Mastectomy (MRM) involves a formal axillary lymph node dissection (Levels I and II). The nodes removed are based on anatomical boundaries, not necessarily the specific drainage pattern of the tumor. * **Option C (Incorrect):** Proximity does not always equal drainage. Due to the complexity of lymphatic channels, the sentinel node may sometimes be anatomically distant from the tumor while still being the first node to receive its drainage. **Clinical Pearls for NEET-PG** * **Identification:** SLN is identified using **Isosulfan blue/Methylene blue dye** (visualized) and/or **Technetium-99m labeled sulfur colloid** (detected via a gamma probe). * **Most Common Indications:** Breast cancer (T1/T2 lesions) and Malignant Melanoma. * **Skip Metastasis:** This refers to a phenomenon where the SLN is negative, but higher-level nodes are positive. While rare, it is a limitation of SLN biopsy. * **Contraindications in Breast Cancer:** Inflammatory breast cancer, multicentric tumors (relative), and clinically palpable axillary nodes (N1/N2).

Question 2: What is the definition of neoadjuvant chemotherapy?

A. Chemotherapy administered concurrently with surgery
B. Chemotherapy administered prior to surgery (Correct Answer)
C. Chemotherapy administered following surgery
D. Chemotherapy administered in conjunction with radiation therapy

Explanation: **Explanation:** **Neoadjuvant chemotherapy** refers to the administration of systemic cytotoxic agents **prior to the primary definitive treatment** (usually surgery). The primary goal is to downstage the tumor, increase the likelihood of a complete (R0) resection, and treat micrometastatic disease early. * **Why Option B is Correct:** The prefix "neo-" (new/before) and "adjuvant" (assisting) signifies therapy given before the main intervention. By shrinking the primary tumor, it can convert an inoperable case into an operable one or allow for breast-conserving surgery instead of a mastectomy. * **Why Options A, C, and D are Incorrect:** * **Option A:** Chemotherapy is rarely given *during* the surgical procedure itself (except for specialized techniques like HIPEC). * **Option C:** This describes **Adjuvant Chemotherapy**, which is given *after* surgery to eliminate residual microscopic disease and reduce recurrence risk. * **Option D:** This describes **Concurrent Chemoradiotherapy (CCRT)**, often used as definitive treatment in cancers like Carcinoma Cervix or Esophagus. **NEET-PG High-Yield Pearls:** 1. **Pathological Complete Response (pCR):** The gold standard for measuring the effectiveness of neoadjuvant therapy; it implies no viable tumor cells remain in the surgical specimen. 2. **Common Indications:** Locally advanced breast cancer (LABC), esophageal cancer, and rectal cancer (often as neoadjuvant chemoradiation). 3. **Window of Opportunity:** It provides an *in vivo* assessment of how sensitive the tumor is to a specific chemotherapy regimen.

Question 3: In TNM classification, what does T3 stand for regarding tumor size?

A. Tumor size >2 cm
B. Tumor size >4 cm (Correct Answer)
C. Tumor size <4 cm
D. Tumor size >4 cm with invasion of adjacent structures

Explanation: The **TNM classification** is the global standard for staging malignant tumors, where **T** describes the size and extent of the primary tumor. In many common solid organ cancers (such as Oral Cavity, Skin, and Salivary Glands), the "Rule of 2s" is often applied for T-staging. ### **Explanation of the Correct Answer** **Option B (>4 cm)** is correct because, in the standard AJCC staging for several major sites (like the oral cavity), the T-stage is defined by size thresholds: * **T1:** ≤2 cm * **T2:** >2 cm but ≤4 cm * **T3:** **>4 cm** (limited to the organ of origin) ### **Analysis of Incorrect Options** * **Option A (>2 cm):** This represents the lower limit for **T2** lesions. A tumor >2 cm but ≤4 cm is classified as T2. * **Option C (<4 cm):** This is a vague descriptor. Tumors <4 cm are categorized as either T1 or T2 depending on whether they are above or below the 2 cm mark. * **Option D (>4 cm with invasion):** While the size is correct, the addition of "invasion of adjacent structures" (like cortical bone, deep tongue muscles, or maxillary sinus) typically upgrades the tumor to **T4a or T4b** (Advanced Local Disease), regardless of the size. ### **High-Yield Clinical Pearls for NEET-PG** 1. **T0 vs. Tis:** T0 means no evidence of a primary tumor, while **Tis** stands for Carcinoma *in situ* (pre-invasive). 2. **Clinical vs. Pathological:** **cTNM** is based on physical exam and imaging; **pTNM** is based on histopathological examination of the resected specimen. 3. **Depth of Invasion (DOI):** In the latest AJCC 8th Edition (Oral Cavity), T-staging now incorporates DOI. For example, a T3 tumor is also defined as any tumor with a **DOI >10 mm**, even if the surface diameter is small. 4. **Sentinel Node Biopsy:** This is the most accurate method for "N" staging in early-stage (T1/T2) tumors with clinically negative necks (cN0).

Question 4: A tumor is represented as T3N2M0. What stage does this indicate?

A. Stage 1
B. Stage 2
C. Stage 3
D. Stage 4 (Correct Answer)

Explanation: ### Explanation The TNM staging system (Tumor, Node, Metastasis) is the global standard for classifying the extent of cancer. In this case, the tumor is staged as **T3N2M0**, which corresponds to **Stage 4** (specifically Stage IV in many solid tumor classifications like Head and Neck or certain GI cancers). **1. Why Stage 4 is Correct:** In the TNM hierarchy, the involvement of regional lymph nodes is a significant prognostic indicator. While "Stage 4" is often associated with distant metastasis (M1), in several major staging systems (such as the AJCC 7th/8th editions for various squamous cell carcinomas), **N2 or N3 nodal involvement** automatically upgrades the disease to Stage IV, even in the absence of distant metastasis (M0). This reflects a high regional tumor burden and a prognosis similar to metastatic disease. **2. Why Other Options are Wrong:** * **Stage 1:** Typically represents small, localized tumors (T1) without any nodal involvement (N0) or metastasis (M0). * **Stage 2:** Usually involves larger localized tumors (T2) but still maintains an N0 status. * **Stage 3:** Generally involves T3 tumors with N0 or limited N1 nodal involvement. Once the nodal status reaches **N2**, the disease typically crosses the threshold into Stage 4. **3. NEET-PG High-Yield Pearls:** * **M1 = Always Stage 4:** Regardless of T or N status, any distant metastasis (M1) is automatically Stage IV. * **Nodal Status:** For many cancers, N0 = Stage I/II, N1 = Stage III, and N2/N3 = Stage IV. * **Exceptions:** Note that staging varies by organ (e.g., in Papillary Thyroid Cancer, age <55 years means any TNM without M1 is Stage I). * **Clinical vs. Pathological:** 'cTNM' is based on imaging/exam; 'pTNM' is based on surgical histopathology.

Question 5: A 60-year-old male is diagnosed with carcinoma of the right lung. CECT of the chest shows a 5x5 cm tumor in the upper lobe and another 2x2 cm tumor nodule in the middle lobe. Which of the following is the treatment of choice?

A. Surgery (Correct Answer)
B. Radiotherapy
C. Chemotherapy
D. Supportive treatment

Explanation: ### Explanation **Correct Option: A. Surgery** The patient presents with two separate tumor nodules in different lobes of the same lung (Right Upper Lobe and Right Middle Lobe). According to the **TNM 8th Edition Staging System** for Lung Cancer: * Tumor nodules in the **same lobe** are classified as **T3**. * Tumor nodules in **different lobes of the same lung** are classified as **T4**. Despite being T4, if there is no evidence of mediastinal lymphadenopathy (N0/N1) or distant metastasis (M0), the disease is classified as **Stage IIIA**. In modern surgical oncology, Stage IIIA (T4N0-1) lung cancer is considered **resectable**. The treatment of choice is a surgical resection (e.g., pneumonectomy or bilobectomy) provided the patient has adequate pulmonary reserve. **Why Incorrect Options are Wrong:** * **B. Radiotherapy:** Primarily used for Stage IIIB/IV or in patients who are medically unfit for surgery. It is not the first-line treatment for resectable T4 disease. * **C. Chemotherapy:** Often used as neoadjuvant or adjuvant therapy in Stage III disease, but it is not the definitive "treatment of choice" when surgical cure is possible. * **D. Supportive treatment:** Reserved for end-stage (Stage IV) palliative care where curative intent is no longer feasible. **High-Yield Clinical Pearls for NEET-PG:** 1. **T-Staging Summary:** * Same Lobe = T3 * Same Lung (different lobe) = T4 * Opposite Lung = M1a 2. **Resectability vs. Operability:** Resectability depends on the tumor stage (TNM), while operability depends on the patient's fitness (FEV1, cardiac status). 3. **Gold Standard:** For early-stage Non-Small Cell Lung Cancer (NSCLC), anatomical resection (Lobectomy) with mediastinal lymph node dissection remains the gold standard.

Question 6: Elevated alpha-fetoprotein (AFP) levels are seen in all of the following conditions except:

A. Hepatoblastoma
B. Seminoma (Correct Answer)
C. Teratoma
D. None of the above

Explanation: **Explanation:** Alpha-fetoprotein (AFP) is a glycoprotein normally produced by the fetal yolk sac and liver. In adult medicine, it serves as a crucial tumor marker for specific germ cell tumors (GCTs) and hepatocellular carcinomas. **Why Seminoma is the Correct Answer:** Pure **Seminomas** (and their ovarian counterpart, Dysgerminomas) **never** produce AFP. If a patient diagnosed with a seminoma shows elevated AFP levels, it indicates the presence of a "mixed germ cell tumor" containing yolk sac elements, and the clinical management must change accordingly. Seminomas are typically associated with elevated **hCG** (in 10-15% of cases) and **LDH**, but never AFP. **Analysis of Other Options:** * **Hepatoblastoma:** This is the most common primary liver tumor in children. It is characterized by extremely high levels of AFP, which is used for both diagnosis and monitoring treatment response. * **Teratoma:** While pure mature teratomas may not secrete markers, teratomas are frequently part of mixed germ cell tumors. In the context of NEET-PG questions, AFP is considered a marker for non-seminomatous germ cell tumors (NSGCTs), which includes yolk sac tumors, embryonal carcinomas, and certain teratomas. **High-Yield Clinical Pearls for NEET-PG:** 1. **Yolk Sac Tumor (Endodermal Sinus Tumor):** This is the most specific tumor associated with high AFP levels (100% of cases). Look for **Schiller-Duval bodies** on histology. 2. **Hepatocellular Carcinoma (HCC):** AFP is the primary screening marker; levels >400 ng/mL in a high-risk patient are highly suggestive. 3. **Rule of Thumb:** * **AFP ↑:** Yolk sac tumor, HCC, Hepatoblastoma. * **hCG ↑:** Choriocarcinoma (100%), Seminoma (15%). * **LDH ↑:** Seminoma (marker of tumor burden/bulk).

Question 7: Which of the following statements is NOT true regarding familial polyposis coli?

A. It is inherited in an autosomal recessive pattern. (Correct Answer)
B. It is associated with fibromas and osteomas.
C. It is associated with brain tumors.
D. It has a 100% incidence of colon carcinoma.

Explanation: ### Explanation **1. Why Option A is the Correct Answer (The False Statement):** Familial Adenomatous Polyposis (FAP) is inherited in an **Autosomal Dominant** pattern, not recessive. It is caused by a germline mutation in the **APC (Adenomatous Polyposis Coli) gene** located on chromosome **5q21**. According to Knudson’s "two-hit hypothesis," an individual inherits one defective allele, and a somatic mutation in the second allele leads to the development of hundreds to thousands of adenomatous polyps. **2. Analysis of Other Options:** * **Option B (Associated with fibromas and osteomas):** This describes **Gardner Syndrome**, a variant of FAP. It includes intestinal polyposis plus extra-colonic manifestations like osteomas (commonly of the mandible), dental abnormalities, and soft tissue tumors (desmoid tumors, fibromas). * **Option C (Associated with brain tumors):** This describes **Turcot Syndrome**, another variant where FAP is associated with CNS malignancies (classically medulloblastoma). * **Option D (100% incidence of colon carcinoma):** This is a hallmark of FAP. If left untreated by prophylactic total proctocolectomy, the progression from adenoma to adenocarcinoma is inevitable, usually by the age of 40. **3. High-Yield Clinical Pearls for NEET-PG:** * **Diagnosis:** Requires >100 polyps on colonoscopy. * **Screening:** Starts at age **10–12 years** with annual flexible sigmoidoscopy. * **Extra-colonic Malignancy:** The second most common cause of death in FAP patients (after colorectal cancer) is **Periampullary Carcinoma** (Duodenal cancer). * **CHRPE:** Congenital Hypertrophy of Retinal Pigment Epithelium is a specific clinical sign seen on fundoscopy in FAP patients.

Question 8: What is the most common symptom of bronchial adenoma?

A. Chest pain
B. Weight loss
C. Recurrent hemoptysis (Correct Answer)
D. Cough

Explanation: **Explanation:** **Bronchial adenomas** (a term historically used to describe a group of low-grade malignant tumors, primarily **Bronchial Carcinoids**) are highly vascular, slow-growing epithelial tumors that typically arise from the central airways (main or lobar bronchi). 1. **Why Recurrent Hemoptysis is Correct:** The hallmark of bronchial adenomas is their **extreme vascularity** and their tendency to grow as endobronchial polypoid masses. Because they arise from the bronchial mucosa and are richly supplied by blood vessels, the overlying mucosa is fragile. Even minor trauma from coughing or tumor erosion leads to **recurrent, often brisk, hemoptysis**. This is the most common presenting symptom, occurring in approximately 50–80% of cases. 2. **Why Other Options are Incorrect:** * **Cough:** While cough is a common symptom due to endobronchial irritation or obstruction, it is non-specific and often secondary to the bleeding or localized collapse. * **Chest Pain:** This is usually a late feature, occurring only if the tumor involves the pleura or causes significant obstructive pleurisy/pneumonia. * **Weight Loss:** Unlike Bronchogenic Carcinoma (Small cell or Squamous cell), bronchial adenomas are slow-growing and rarely cause systemic paraneoplastic "wasting" or cachexia early in the disease. **Clinical Pearls for NEET-PG:** * **Most Common Type:** Carcinoid tumor (80–90% of "adenomas"). * **Classic Presentation:** A young patient (often non-smoker) presenting with recurrent hemoptysis and localized wheeze or "unresolved pneumonia" (due to ball-valve obstruction). * **Diagnosis:** Bronchoscopy is the gold standard as most are central. However, biopsy carries a **high risk of bleeding** due to vascularity. * **Carcinoid Syndrome:** Rare in bronchial carcinoids (unlike GI carcinoids) unless there are extensive liver metastases.

Question 9: Which lymph node is involved in M1 stage of gallbladder cancer?

A. Inter-aortocaval node (Correct Answer)
B. Superior mesenteric node
C. Coeliac node
D. Pancreaticoduodenal node

Explanation: ### Explanation In gallbladder cancer (GBC), the lymphatic drainage follows a predictable, sequential pattern. Understanding the distinction between **regional** and **distant** lymph nodes is crucial for accurate TNM staging. **1. Why Option A is Correct:** According to the **AJCC 8th Edition** staging for gallbladder cancer, the **inter-aortocaval nodes** (located behind the head of the pancreas and around the great vessels) are considered **distant lymph node metastases (M1)**. Involvement of these nodes signifies systemic spread, rendering the disease unresectable for curative intent. **2. Why the Other Options are Incorrect:** The lymphatic spread of GBC occurs in three levels, all of which are considered **regional (N-stage)**, not distant (M-stage): * **Level I (N1):** Includes the cystic duct node (Lund’s/Calot’s node) and pericholedochal nodes. * **Level II (N2):** Includes the **pancreaticoduodenal (Option D)**, peripancreatic (head only), and portal vein nodes. * **Level III (N2):** Includes the **coeliac (Option C)** and **superior mesenteric (Option B)** nodes. * *Note:* While Options B, C, and D represent advanced nodal involvement (N2), they are still classified under the "N" category. Only nodes beyond these, like the inter-aortocaval or para-aortic nodes, transition the stage to **M1**. **High-Yield Clinical Pearls for NEET-PG:** * **Most common site of distant metastasis:** Liver. * **Sentinel node of the gallbladder:** Lund’s node (Node of Calot). * **N-staging update:** AJCC 8th edition now classifies N stage based on the *number* of positive nodes (N1: 1–2 nodes; N2: ≥3 nodes), but the anatomical boundary for M1 remains the inter-aortocaval/para-aortic station. * **Investigation of choice:** Contrast-Enhanced CT (CECT) is the gold standard for staging and assessing resectability.

Question 10: What are the risk factors for anal carcinoma?

A. Human Papillomavirus (HPV) infection
B. Smoking
C. Cervical carcinoma
D. All of the above (Correct Answer)

Explanation: **Explanation:** Anal carcinoma (specifically Squamous Cell Carcinoma) shares a similar pathophysiology with cervical cancer, primarily driven by persistent infection with high-risk strains of **Human Papillomavirus (HPV)**, most commonly types 16 and 18. * **HPV Infection (Option A):** This is the most significant risk factor, present in over 80-90% of cases. The virus integrates into the host genome, leading to the overexpression of E6 and E7 oncoproteins, which inactivate tumor suppressor genes p53 and Rb. * **Smoking (Option B):** Cigarette smoking is an independent risk factor for anal cancer. Carcinogens in tobacco smoke can reach the anal mucosa through systemic circulation or local deposition, promoting malignant transformation. * **Cervical Carcinoma (Option C):** Patients with a history of cervical, vaginal, or vulvar dysplasia/carcinoma are at a significantly higher risk. This is due to the "field effect" of HPV infection across the anogenital tract and shared lymphatic drainage patterns. **Clinical Pearls for NEET-PG:** 1. **HIV Status:** HIV-positive individuals (especially MSM - men who have sex with men) have the highest incidence of anal cancer due to immunosuppression and increased HPV prevalence. 2. **Anal Intraepithelial Neoplasia (AIN):** This is the precursor lesion (similar to CIN in the cervix). 3. **Anatomy:** Tumors above the dentate line are typically columnar/transition zone, while those below are squamous. 4. **Treatment:** Unlike most GI cancers, the primary treatment for anal canal SCC is **Nigro Protocol** (Chemoradiotherapy with 5-FU and Mitomycin C), not surgery. Surgery (Abdominoperineal Resection) is reserved for salvage.

Practice by Chapter

Cancer Biology Basics

Practice Questions

Principles of Cancer Therapy

Practice Questions

Screening and Early Detection

Practice Questions

Surgical Staging

Practice Questions

Surgical Resection Principles

Practice Questions

Lymphadenectomy

Practice Questions

Management of Metastatic Disease

Practice Questions

Combined Modality Therapy

Practice Questions

Targeted Therapy Concepts

Practice Questions

Cancer Survivorship

Practice Questions

Palliative Surgical Interventions

Practice Questions

Ethics in Cancer Care

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free